Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis

Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis

Background: Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis and leads to serious complications if left untreated. Some strains of Mycobacterium tuberculosis are multi-drug resistant and require treatment with newer drugs. Bedaquiline based treatment regimens have been used...

Full description

Bibliographic Details
Main Authors:	Obaid Ur Rehman, Eeshal Fatima, Abraish Ali, Umar Akram, Abdulqadir Nashwan, Faryal Yunus
Format:	Article
Language:	English
Published:	Elsevier 2024-02-01
Series:	Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Subjects:	Bedaquiline Efficacy Drug resistance Meta-analysis Tuberculosis Multidrug resistant
Online Access:	http://www.sciencedirect.com/science/article/pii/S240557942300061X

Similar Items

Bedaquiline in the treatment regimen of multidrugresistant tuberculosis (clinical observation)
by: V. A. Aksenova, et al.
Published: (2020-11-01)

Efficacy and safety of regimen containing bedaquiline in children with drug-resistant tuberculosis
by: V. A. Aksenova, et al.
Published: (2021-10-01)

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation
by: Anna Starshinova, et al.
Published: (2022-11-01)

Bedaquiline: Current status and future perspectives
by: Saeed Khoshnood, et al.
Published: (2021-06-01)

Bedaquiline resistance in Mycobacterium tuberculosis during antimycobacterial therapy and its impact on clinical outcomes (clinical cases)
by: O. M. Raznatovska, et al.
Published: (2023-03-01)

Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis
by: Yuhong Liu, et al.
Published: (2021-01-01)

Early efficacy of individual regimens containing bedaquiline in patients with drug resistant tuberculosis
by: Oki Nugraha Putra, et al.
Published: (2023-01-01)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
by: Jing-Tao Gao, et al.
Published: (2021-03-01)

Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians
by: Citra Cesilia, et al.
Published: (2023-01-01)

Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience
by: Alena Skrahina, et al.
Published: (2016-01-01)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
by: Jian Du, et al.
Published: (2021-05-01)

A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea
by: Tae Sun Shim, et al.
Published: (2023-01-01)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
by: Shereen Katrak, et al.
Published: (2021-05-01)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
by: Francesco Pecora, et al.
Published: (2021-05-01)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
by: Lawrence Mbuagbaw, et al.
Published: (2019-05-01)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
by: Hossein Hatami, et al.
Published: (2022-05-01)

Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study
by: Rong Li, et al.
Published: (2023-08-01)

Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review
by: Oki Nugraha Putra, et al.
Published: (2023-01-01)

Bedaquiline in the treatment of extensively drugresistant tuberculosis
by: T. I. Morozova, et al.
Published: (2022-04-01)

Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis
by: Jinmeng Li, et al.
Published: (2021-09-01)

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis
by: Catherine Berry, et al.
Published: (2022-06-01)

Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis
by: Jin Shi, et al.
Published: (2023-10-01)

Evaluation of the effectiveness of bedaquiline and delamanid treatment among children and adolescents with multi-drug-resistant pulmonary tuberculosis
by: M.I. Sakhelashvili, et al.
Published: (2023-03-01)

Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis
by: Oki Nugraha Putra, et al.
Published: (2022-01-01)

Emerging bedaquiline resistance: A threat to the global fight against drug-resistant tuberculosis
by: Prakasini Satapathy, et al.
Published: (2024-03-01)

Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients
by: Ge Shao, et al.
Published: (2023-03-01)

Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis
by: Camus Nimmo, et al.
Published: (2024-02-01)

Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan
by: Sheng-Han Wu, et al.
Published: (2021-10-01)

Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study
by: Ju Hwan Kim, et al.
Published: (2023-08-01)

Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China
by: Wencong He, et al.
Published: (2021-09-01)

Bedaquiline practice in treatment of extensively drug-resistant mycobacterium tuberculosis in children: Clinical cases
by: A. A. Akzhigitova, et al.
Published: (2022-05-01)

Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data
by: I Gusti Agung Ayu Putu Sri Darmayani, et al.
Published: (2022-07-01)

Extensively drug-resistant tuberculosis treated with bedaquiline: A case report in the particularly vulnerable tribal group of Madhya Pradesh, India
by: Prashant Mishra, et al.
Published: (2021-01-01)

Comparison of efficacy of bedaquiline and moxifloxacin in drug resistant pulmonary tuberculosis. A prospective observational study
by: Govind Desai, et al.
Published: (2022-05-01)

Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China
by: Tong E, et al.
Published: (2023-10-01)

Effectiveness and safety of bedaquiline-based, modified all-oral 9–11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam
by: Thi Mai Phuong Nguyen, et al.
Published: (2023-01-01)

Mycobacterium tuberculosis – atpE gene profile of bedaquiline-treated pulmonary tuberculosis patients at the referral hospital Dr. Soetomo, Indonesia
by: Muhamad Frendy Setyawan, et al.
Published: (2023-01-01)

Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China
by: Jian Yang, et al.
Published: (2020-10-01)

Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China
by: Abela Mpobela Agnarson, et al.
Published: (2020-02-01)

Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis
by: Qi An, et al.
Published: (2023-09-01)